Home / Business and Economy / Incyte Beats Revenue Estimates, But Full-Year Guidance Falls Short
Incyte Beats Revenue Estimates, But Full-Year Guidance Falls Short
28 Jul
Summary
- Incyte's Q2 revenue reached $1.67 billion, exceeding expectations.
- The company's full-year revenue guidance was lowered, missing estimates.
- Non-GAAP profit per share significantly surpassed analyst consensus.
Incyte Corporation announced its second quarter CY2026 financial results, reporting revenue of $1.67 billion. This figure represented a significant year-on-year increase of 37.7% and beat analyst expectations by 11.3%. The biopharmaceutical company also achieved a non-GAAP profit of $3.09 per share, which was 43.9% higher than the consensus estimate.
Despite the strong quarterly performance, Incyte's guidance for the full year now projects $5.20 billion in revenue at the midpoint. This updated forecast comes in 9.2% below what analysts had predicted, indicating a potential slowdown. The company's operating margin stood at 41.7%, a slight decrease from the previous year's 43.6%.
Founded in 1991, Incyte has transitioned from a genomics research firm to a commercial-stage developer of therapeutics for cancer and inflammatory diseases. Its historical revenue growth has been robust, with a 16.7% annualized rate over the last five years, and a more recent acceleration to 22.8% over the past two years.
